Business
CytoSorbents and Aferetica Announce the Commercial Launch in Italy of the PerSorb™ Adsorber and PerLife™ Organ Perfusion System, respectively, at the European Society of Organ Transplantation Congress
MONMOUTH JUNCTION, N.J. and BOLOGNA, Italy, Aug. 30, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO) and Aferetica srl (Italy), two pioneers in
About this update from Cytosorbents Corporation
[{"type":"text","content":"MONMOUTH JUNCTION, N.J. and BOLOGNA, Italy, Aug. 30, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO) and Aferetica srl (Italy), two pioneers in intensive care immunotherapy and blood purification, announce the commercial launch of Aferetica's PerLife™ ex vivo organ perfusion system for kidney and liver transplant and CytoSorbents' PerSorb™ adsorber, based on the CytoSorbents ECOS-300CY™ sorbent technology to remove inflammatory mediators during ex vivo organ perfusion, at the European Society of Organ Transplantation (ESOT) Congress in Milan, Italy from August 29 – September 1, 2021.\n\n \n \n \n \n \n \n\n \nCytoSorbents and Aferetica Announce the Commercial Launch of the PerSorb™ Adsorber and PerLife™ Organ Perfusion SystemThe PerLife and PerSorb technologies will be showcased in Aferetica's Booth #26 in the main exhibit hall and highlighted at the company-sponsored symposium \"From Organ Preservation to Organ Regeneration\" on Tuesday, August 31, 2021 from 1:15-2:15PM CEST in Turquoise Room 1.\nChairs: \nL. De Carlis (University of Milan Bicocca, Italy) and F. D'Ovidio (Columbia University, USA)Speakers:\nG. Remuzzi (Mario Negri Institute, Italy) Expanding the Organ Transplant Pool: The Role of Ex Vivo Perfusion S. Hosgood (University of Cambridge, U.K.)The Inflammatory Mediators and Graft Function: The Kidneys M. Boffini & M. Rinaldi (University of Turin, Italy)Cytokines, Transplantability, Primary Graft Dysfunction, Survival: The Lungs F. Dazzi (King's College, U.K.)Mesenchymal Stromal Cells: Should they be Integrated in Machine Perfusion Devices?Dr. Mauro Atti, Chief Executive Officer of Aferetica stated, \"Today is a significant step forward for the PerLife project with the commercial launch at the ESOT Congress, which sets the stage for the international launch of the combined PerLife and PerSorb system. We believe we can revolutionize the world of transplantation with the first system capable of supporting both hypothermic and normothermic organ support in one machine. We have reached this milestone thanks to many academic collaborations with leading national and international experts and our partnership with CytoSorbents. We take great pride and satisfaction in this accomplishment.\"\nDr. Atti continued, \"At tomorrow's symposia, key opinion leaders will present studies with results showing the importance ...